Zacks Research Issues Positive Estimate for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Stock analysts at Zacks Research upped their Q2 2026 earnings per share estimates for shares of Halozyme Therapeutics in a report issued on Monday, September 1st. Zacks Research analyst Team now expects that the biopharmaceutical company will earn $1.24 per share for the quarter, up from their previous forecast of $1.20. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same period in the prior year, the firm earned $0.91 EPS. The firm’s revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS.

A number of other research firms have also recently commented on HALO. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday. The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a “neutral” rating and a $55.00 target price on the stock. Leerink Partnrs lowered Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 13th. Leerink Partners downgraded shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price target for the company. in a research note on Tuesday, May 13th. Finally, JMP Securities boosted their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $67.11.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $74.93 on Thursday. The business’s 50-day moving average is $62.80 and its two-hundred day moving average is $59.81. The company has a market capitalization of $8.76 billion, a P/E ratio of 17.15, a P/E/G ratio of 0.40 and a beta of 1.19. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. Halozyme Therapeutics has a fifty-two week low of $42.01 and a fifty-two week high of $75.46.

Institutional Trading of Halozyme Therapeutics

Hedge funds have recently bought and sold shares of the company. Wealth Preservation Advisors LLC acquired a new stake in Halozyme Therapeutics during the first quarter worth approximately $32,000. SVB Wealth LLC purchased a new position in Halozyme Therapeutics during the first quarter worth approximately $33,000. Bessemer Group Inc. raised its stake in Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 207 shares during the period. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics during the fourth quarter worth approximately $29,000. Finally, Newbridge Financial Services Group Inc. purchased a new position in Halozyme Therapeutics during the second quarter worth approximately $32,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the sale, the director owned 46,952 shares in the company, valued at approximately $3,459,423.36. This trade represents a 7.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $74.44, for a total transaction of $1,488,800.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at approximately $54,618,042.36. This trade represents a 2.65% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 104,000 shares of company stock worth $6,316,120. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.